New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. Pelosi hits Trump on LA: Where was National Guard on Jan. 6 ...

Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The ...

NEW YORK, June 26, 2024 /PRNewswire/ -- Formation Bio, a tech-driven and AI-native pharma company, announced today that it has raised $372MM of Series D financing. The financing was led ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of ...